{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=60", "query": { "condition": "Carcinoma, Bronchogenic", "page": 60 }, "page_size": 10 }, "pagination": { "page": 60, "page_size": 10, "total_count": 3591, "total_pages": 360, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=61&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=59&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T03:45:12.935Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00533429", "title": "Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-10", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 12, "location_summary": "Bentonville, Arkansas • Chicago, Illinois • Galesburg, Illinois + 9 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00533429" }, { "nct_id": "NCT00005037", "title": "Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2000-01", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2014-05-06", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Waukesha, Wisconsin", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Waukesha", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005037" }, { "nct_id": "NCT04698681", "title": "NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer", "Non-squamous Non-small-cell Lung Cancer", "Non-Squamous Non-Small Cell Neoplasm of Lung", "KEAP1 Gene Mutation", "NRF2 Mutation", "NFE2L2 Gene Mutation" ], "interventions": [], "intervention_types": [], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-01-19", "completion_date": "2022-02-09", "has_results": false, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 63, "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04698681" }, { "nct_id": "NCT00023673", "title": "Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "three-dimensional conformal radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 63, "start_date": "2001-07", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 40, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Burbank, California + 30 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023673" }, { "nct_id": "NCT05783622", "title": "Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Colorectal Carcinoma", "Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "JANX008", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janux Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 130, "start_date": "2023-04-19", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 18, "location_summary": "Duarte, California • Sacramento, California • San Diego, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05783622" }, { "nct_id": "NCT05211895", "title": "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 791, "start_date": "2022-02-18", "completion_date": "2027-09-08", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 32, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05211895" }, { "nct_id": "NCT03639194", "title": "A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "ABBV-011", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2018-10-24", "completion_date": "2024-01-25", "has_results": false, "last_update_posted_date": "2024-02-09", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Sacramento, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639194" }, { "nct_id": "NCT00899457", "title": "Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy, no Evidence of Disease", "Lung Cancer" ], "interventions": [ { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "biologic sample preservation procedure", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "bronchoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2008-04", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2014-06-24", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899457" }, { "nct_id": "NCT05274451", "title": "A Study to Investigate LYL797 in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "TNBC - Triple-Negative Breast Cancer", "Non-small Cell Lung Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Non-Small Cell Carcinoma of Lung, TNM Stage 4", "Advanced Breast Cancer", "Advanced Lung Carcinoma", "NSCLC", "NSCLC, Recurrent", "NSCLC Stage IV", "Relapsed Cancer", "Relapse/Recurrence", "Recurrent Breast Cancer", "Recurrent NSCLC", "Platinum-resistant Ovarian Cancer", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Endometrioid Tumor", "High Grade Serous Carcinoma", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "LYL797", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2022-03-29", "completion_date": "2024-11-27", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274451" }, { "nct_id": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Squamous Cell Carcinoma of Head and Neck", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Sarcoma", "Endometrial Cancer", "Melanoma", "Castration Resistant Prostatic Cancer", "Cervical Cancer", "Colorectal Cancer", "Gastric Cancer", "Gastro-esophageal Cancer", "Pancreas Cancer", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Platinum-resistant Ovarian Cancer", "Breast Cancer", "Ovarian Cancer", "Esophageal Squamous Cell Cancer (SCC)" ], "interventions": [ { "name": "MGC026 Dose Escalation", "type": "BIOLOGICAL" }, { "name": "MGC026 Dose for Expansion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-03-06", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-26T03:45:12.935Z", "location_count": 7, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06242470" } ] }